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Abstract
Background: Angiogenesis appears to play an important role in ovarian cancer. Vascular endothelial growth factor 
(VEGF) has recently been implicated as a therapeutic target in ovarian cancer. The tissue inhibitor of metalloproteinase 
1 (TIMP-1) is involved in tissue invasion and angiogenesis. The application of serum TIMP-1 and VEGF to monitor 
primary therapy and predict clinical outcome of patients with ovarian cancer is unclear.
Methods: Patients with epithelial ovarian cancer who presented for primary surgery were included in this study. A total 
of 148 serum samples from 37 patients were analyzed. Samples were prospectively collected at 4 predefined time 
points: 1. before radical debulking surgery, 2. after surgery and before platinum/taxane based chemotherapy, 3. during 
chemotherapy, 4. after chemotherapy. Serum VEGF-165 and TIMP-1 as well as CA-125 were quantified by ELISA or 
ECLIA and correlation with response and long-term clinical outcome was analyzed.
Results: Serum levels of all markers changed substantially during first-line therapy. High CA-125 (p = 0.002), TIMP-1 (p 
= 0.007) and VEGF-165 (p = 0.02) after chemotherapy were associated with reduced overall survival. In addition, 
elevated CA-125 (p < 0.001) and VEGF-165 (p = 0.006) at this time point predicted poor progression-free survival. TIMP-
1 and VEGF-165 were closely correlated at all time-points during therapy.
Conclusions: TIMP-1 and VEGF serum levels changed significantly during first-line therapy of ovarian cancer patients 
and predicted prognosis. These findings support the role of angiogenesis in ovarian cancer progression and the use of 
antiangiogenic therapy.
Background
Epithelial ovarian cancer accounts for the highest mortal-
ity among all gynecologic malignancies in the Western
world. The American Cancer Society estimates more
than 20.000 new cases and 15.000 deaths due to this dis-
ease each year in the United States [1]. Because of the
absence of specific early symptoms most patients are
diagnosed at an advanced stage with extensive intra-
abdominal disease and peritoneal carcinomatosis. Initial
treatment for ovarian cancer consists of aggressive surgi-
cal cytoreduction and six cycles of carboplatin-paclitaxel
combination chemotherapy [2]. Most patients will
achieve radiologic and serologic complete remission after
first-line therapy. However, 75% of these patients will
relapse and eventually die of their disease [3]. Clinical tri-
als of the past decade have mainly focused on adding
cytostatic agents to the established combination of carbo-
platin and paclitaxel to improve therapy. Unfortunately,
this approach provided no benefit and development of
new therapeutic strategies is required [4].
Enhanced understanding of the underlying biology of
ovarian cancer has recently led to the discovery of molec-
ular targeted therapies to accompany chemotherapy and
potentially improve outcome [5]. Currently, angiogenesis
appears to be the most promising therapeutic target for
ovarian cancer [6-9] and large phase III trials with anti-
angiogenic therapeutics are conducted worldwide. In this
context, the development of predictive and prognostic
markers to optimize the use of these targeted approaches
in clinical practice is one of the most important issues.
Established prognostic factors in patients with epithelial
ovarian cancer are International Federation of Gynecol-
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ogy and Obstetrics (FIGO) stage, residual tumor volume
after primary surgical cytoreduction, tumor grading and
histological subtype [10]. Several other clinical and bio-
logical factors including serum cancer antigen 125 (CA-
125) have been assessed for prognostic and predictive rel-
evance [11,12].
CA-125 is a high molecular weight glycosylated mem-
brane protein that can be detected in serum and is ele-
vated in more than 80% of patients with ovarian cancer. It
is used as a marker to assess therapy-response and pro-
gression [13,14]. A rapid decrease of CA-125 during che-
motherapy predicts a favourable prognosis and might
also serve as a marker for disease recurrence. However,
20% of ovarian cancers have low or no expression of CA-
125, thus, additional serum markers are required.
Degradation of basement membranes and extracellular
matrix as well as neovascularisation are essential features
in the progress of ovarian cancer. Vascular endothelial
growth factor (VEGF) and tissue inhibitor of metallopro-
teinase-1 (TIMP-1) are involved in these processes and
might therefore serve as potential biomarkers in ovarian
cancer patients [15,16].
The aim of the current study was to evaluate the role of
serum VEGF-165 and TIMP-1 to monitor therapy and
predict clinical outcome in patients with ovarian cancer
in comparison to established clinicopathological parame-
ters and CA-125.
Methods
Patients
Patients with epithelial ovarian cancer who presented for
primary surgery at the University Medical Center Ham-
burg-Eppendorf between 1996 and 2004 were included in
this study. A total of 148 serum samples from 37 patients
were analyzed. Detailed patient characteristics are listed
in Table 1. Clinicopathologic factors were evaluated by
reviewing medical charts and pathological records. Tis-
sue slides were reviewed for histological classification and
clinical outcome was followed from the date of surgery to
the date of death or until the end of 2007. Response to
therapy was evaluated with the biomarker CA-125. All
patients gave written informed consent to access their tis-
sue/serum and to review their medical records according
to our investigational review board and ethics committee
guidelines. The use of medical records, serum and tumor
tissue was approved by the ethics committee of the Medi-
cal Board Hamburg (reference number #190504).
Serum samples
Serum samples were collected at 4 predefined time-
points: 1. before surgery (within 7 days before surgery); 2.
after surgery (within 7 days after surgery) and before che-
motherapy; 3. during chemotherapy (within 3 weeks of
the third cycle of chemotherapy); 4. after chemotherapy
Table 1: Patient characteristics
No. of patients 37
Age (years)
mean 58
median 61
range 26-78
FIGO-Stage
I1
II 1
III 29
IV 6
Histologic subtype
serous 31
endometriod 1
clear cell 1
undifferentiated 4
Grading
10
29
32 7
not determined/unknown 1
Lymph node metastasis
pN0 11
pN1 18Mahner et al. BMC Cancer 2010, 10:139
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(during the first follow-up visit 3 months after the last
cycle of chemotherapy).
After centrifugation at 3400 rpm for 10 min, the super-
natants were stored at -20°C before use.
Quantitative analysis of serum VEGF-165 and TIMP-1 levels
Serum VEGF-165 and TIMP-1 were quantified by com-
mercially available ELISA (Siemens Healthcare Diagnos-
tics, Tarrytown, USA). The serum samples and controls
were diluted 1:10 (VEGF-165) and 1:50 (TIMP-1) with
sample diluent buffer (containing bovine serum albumin,
buffer salts and 0.09% sodium acide). One hundred
microliters of the standards, diluted control samples and
diluted serum samples were dispensed into 96-well plates
(coated with an anti-human monoclonal antibody) and
incubated for 1.5 hours at 37°C (VEGF-165) or 30 min-
utes at room temperature (TIMP-1). Wells were washed
and one hundred microliters of the detection antibody
(containing biotinylated anti-VEGF-165 monoclonal anti-
body or alkaline phosphatase-labeled anti-TIMP-1 anti-
body, respectively) were added.
VEGF-165 plates were incubated for one hour at 37°C,
washed and further incubated with one hundred microli-
ters of streptavidin alkaline-phosphatase-labeled conju-
gate for one hour at room temperature. After washing,
one hundred microliters of chromogenic substrate (Blue-
Phos substrate) were added for 45 minutes at room tem-
perature. The reaction was stopped with one hundred
microliters EDTA-stop solution and absorbance was read
at 650 nm by an automated plate-reader (Tecan,
Crailsheim, Germany).
TIMP-1 plates were incubated for 30 minutes at room
temperature. After washing, one hundred microliters of
chromogenic pNPP-substrate was added for 25 minutes
at room temperature in the dark. The reaction was
stopped with one hundred microliters of EDTA-stop
solution and absorbance was read at 405 nm by auto-
mated plate-reader (Tecan, Crailsheim, Germany).
The VEGF-165 and TIMP-1 concentration was esti-
mated from the standard curve. Each sample, standard
and control were analyzed in duplicate.
Quantitative analysis of CA-125
CA-125 serum levels were quantified using the second-
generation electrochemiluminescence immunoassay
(ECLIA) and the Roche Modular Analytics E170 system
(Elecsys module, Roche Diagnostics, Mannheim, Ger-
many) with 20 μl serum samples.
Statistical analysis
All statistical analyses were conducted using SPSS soft-
ware version 15.0 (SPSS Inc., Chicago, IL, USA). Changes
in the serum level of each marker during therapy were
calculated separately using the Wilcoxon test comparing
paired samples at successive time points for individual
patients.
Correlations between serum CA-125, VEGF-165 and
TIMP-1 concentrations and tumor characteristics were
calculated by Chi-square tests. For this purpose, cases
were divided into two groups of equal size for each
marker at each time-point using the median value as cut-
off. The resulting groups were compared regarding the
following parameters: age: <61 years versus 61 years and
older; ascites: <500 ml versus >500 ml; residual tumor
NX 8
Perioperative Ascites
<500 ml 15
>500 ml 21
not determined 1
Residual tumor after 
surgery
microscopic 22
macroscopic 14
not determined 1
Survival (months)
progression-free survival
mean 20
median 16
range 2-71
overall survival
mean 36
median 32
range 8-98
Table 1: Patient characteristics (Continued)Mahner et al. BMC Cancer 2010, 10:139
http://www.biomedcentral.com/1471-2407/10/139
Page 4 of 13
after surgery: microscopic versus macroscopic; lymph
node status: no metastasis versus lymph-node metastasis;
grading: G2 versus G3. Correlations between serum
VEGF-165 and TIMP-1 concentrations and treatment
response according to CA-125 decrease were evaluated
by pair wise Pearson-correlations, assessing the coher-
ence of continuous serum values of VEGF-165 and
TIMP-1 and the relative decrease of CA-125 during ther-
apy.
Kaplan-Meier analysis of progression-free survival
(PFS) and overall survival (OS) was performed using the
same groups. Survival probabilities were compared with
the log-rank test. All tests were performed at a signifi-
cance level of p = 0.05.
Results
Patients
A total of 37 patients were included in this study; detailed
characteristics are listed in Table 1. All patients under-
went radical surgery including hysterectomy, bilateral sal-
pingo-oophorectomy, appendectomy, infragastric
omentectomy and systematic pelvic and paraaortic
lymphadenectomy as well as resection of all visible tumor.
In the majority of patients, complete debulking could be
achieved (22 patients with microscopic residual tumor).
All patients received platinum based first-line combina-
tion-chemotherapy. According to a decrease in CA-125
serum concentrations, all patients responded to first-line
treatment except for one (median decrease in CA-125
was 95% (range 54%-100%). Median follow up time was
29 months. In the study cohort, progression free survival
ranged between 2 and 71 months with a median of 17
months; median overall survival was 44 months and
ranged from 6-97 months.
Serum concentration of CA-125, TIMP-1 and VEGF-165 
duringfirst-line therapy
Serum concentrations of CA-125, VEGF-165 and TIMP-
1 at the respective time-points are listed in Table 2. CA-
125 decreased significantly after surgery whereas the
serum concentrations of TIMP-1 and VEGF-165
increased (Figure 1). During first-line chemotherapy the
serum concentrations of CA-125, TIMP-1 and VEGF-165
decreased significantly compared to the previous time-
point. Further significant decrease after the end of che-
motherapy was only observed for CA-125, while TIMP-1
and VEGF-165 remained unchanged. Compared to initial
serum levels before surgery, CA-125, TIMP-1 and VEGF-
165 during and after chemotherapy also decreased signif-
icantly (during chemotherapy: p < 0.001, p = 0.002, p =
0.026 and after Chemotherapy: p < 0.001, p < 0.001, p =
0.001, respectively). Linked data for the different markers
in each patient are presented in Figure 2.
Correlation between serum concentration of CA-125, TIMP-
1 and VEGF-165 and clinicopathological factors, response, 
progression and survival
The serum values of each marker were divided in two
g r o u p s  ( h i g h  a n d  l o w )  a t  e a c h  t i m e - p o i n t  u s i n g  t h e
median as cut-off value. Correlations between CA-125,
TIMP-1 and VEGF-165 and progression and survival are
listed in Table 3. Correlations between serum markers
and clinicopathological parameters are listed in Table 4.
Correlations between serum VEGF-165 and TIMP-1 con-
centrations and treatment response according to CA-125
are shown in Table 5.
High serum concentrations of CA-125 before surgery
were significantly associated with age (p = 0.046) and
large ascites volume (p = 0.004). Increased CA-125 after
debulking surgery was associated with improved overall
survival (p = 0.033) and low CA-125 after chemotherapy
was associated with improved progression-free (p <
0.001) and overall survival (p = 0.002, Figure 3).
High TIMP-1 concentration after chemotherapy was
associated with decreased overall survival (p = 0.007) and
patients with large ascites volume had higher TIMP-1
concentrations at this time point (p = 0.032).
High VEGF-165 before (p = 0.043) as well as after che-
motherapy (p = 0.006) was associated with decreased
progression-free survival, while high serum-concentra-
Table 2: Serum concentrations of CA-125, TIMP-1 and VEGF at different time-points during therapy
Before surgery After surgery/before CTX during CTX after CTX
mean median range mean median range mean median range mean median range
CA-125 
[kU/L]
1948 413 20-
20880
325 84 15-5965 113 21 6-2562 72 15 5-1429
TIMP-1 
[ng/mL]
451 403 273-887 573 529 323-
1000
377 351 204-616 371 333 209-990
VEGF 
[pg/mL]
231 171 25-791 355 272 85-1133 176 139 11-558 192 147 11-960Mahner et al. BMC Cancer 2010, 10:139
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tion of VEGF-165 after chemotherapy was also associated
with decreased overall survival (p = 0.02).
CA-125 concentration before surgery was inversely
correlated with VEGF-165 concentration before surgery
(r = -0.460; p = 0.01). No inter-marker-correlation was
observed for the other factors except for a constant corre-
lation between VEGF-165 and TIMP-1 before surgery (r
= 0.467; p = 0.008), after surgery (r = 0.522; p = 0.002),
during chemotherapy (r = 0.437; p = 0.009) and after che-
motherapy (r = 0.408; p = 0.017).
Discussion
To investigate the role of new serologic biomarkers in
therapy monitoring and to determine their potential
prognostic significance in ovarian cancer, TIMP-1,
VEGF-165 and CA-125 were analyzed in 148 serum sam-
ples from 37 patients with epithelial ovarian cancer. We
could demonstrate for the first-time that changes of
VEGF-165 and TIMP-1 during first-line therapy of ovar-
ian cancer are substantial and closely correlated. In addi-
tion, we found a potential prognostic and predictive role
for TIMP-1 and VEGF-165.
Biomarkers play an important role in the management
of ovarian cancer in several aspects. These include moni-
toring response to treatment, estimating prognosis and
predicting response to specific drugs. Of all serologic
markers, CA-125 is best established in ovarian cancer. In
the follow-up of patients, rising serum concentrations
correlate with disease progression in approximately 90%
of cases [14]. It can also be used as a surrogate marker for
response to chemotherapy, as a decrease in CA-125 by
50-75% correlated with response in several trials [17]. In
the current study, we used CA-125 as 'benchmark bio-
marker' for comparison with new potential markers. As
expected, CA-125 levels were high before surgery and
decreased substantially during first-line therapy (Table 2,
Figure 1). It was significantly associated with ascites vol-
ume (p = 0.004, Table 3), a correlation that has previously
been described for ovarian cancer as well as other malig-
nancies [18]. We observed no correlation between preop-
erative CA-125 and survival but a weak, yet significant
positive correlation between elevated pre-chemothera-
peutic CA-125 and overall survival (p = 0.033). This cor-
relation might just reflect the controversial role of pre-
treatment CA-125 in ovarian cancer: Some studies found
a prognostic relevance while others failed to demonstrate
this impact [11,19,20]. Due to these inconclusive findings,
pre-treatment CA-125 has currently no clinical role
before initiation of first-line therapy. Patients with low
serum CA-125 at the end of first-line therapy had a
favourable progression-free (p < 0.001) and overall sur-
vival (p = 0.002, Figure 3). Our results are consistent with
other studies and confirm the utility of CA-125 as marker
for ovarian cancer surveillance [11,21]. However, CA-125
has several limitations. Up to 20% of ovarian cancers are
CA-125 negative despite substantial tumor burden [22].
In addition, more than 50% of patients with normalized
CA-125 at the end of therapy still have persistent disease
[23]. Finally, rising CA-125 does not always precede dis-
ease recurrence, thus, additional serum markers are
required.
Figure 1 CA-125 [kU/L] (A), TIMP-1 [ng/L] (B) and VEGF [pg/L] (C) 
before and after surgery (=before chemotherapy) and during and 
after chemotherapy (Wilcoxon Tests comparing paired samples 
at successive time points for individual patients).
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Figure 2 CA-125 [kU/L] (A), TIMP-1 [ng/L] (B) and VEGF [pg/L] (C) before and after surgery (=before chemotherapy) and during and after 
chemotherapy presented as linked data for each patient.
VEGF after 
chemotherapy
VEGF during 
chemotherapy
VEGF after surgery VEGF before surgery
1,500
1,200
900
600
300
0
 
TIMP1 after 
chemotherapy
TIMP1 during 
chemotherapy
TIMP1 after surgery TIMP1 before surgery
1,500
1,200
900
600
300
 
CA 125 after 
chemotherapy 
CA 125 during 
chemotherapy
CA 125 after surgery CA 125 before surgery
5,000
4,500
4,000
3,500
3,000
2,500
2,000
1,500
1,000
500
0
 
A
B
CMahner et al. BMC Cancer 2010, 10:139
http://www.biomedcentral.com/1471-2407/10/139
Page 7 of 13
Angiogenesis has been established as a crucial feature
of tumor development, growth and spread [24]. VEGF is
the most prominent angiogenic molecule and has been
shown to parallel tumor growth and metastasis in various
cancer types [25] and is currently the most promising tar-
get for anti-angiogenic therapy in ovarian cancer [6-8]. In
contrast to other targeted therapies like trastuzumab for
breast cancer [26], no predictive marker has been estab-
lished so far for bevacizumab treatment. VEGF could play
a role in this situation. Although there is abundant evi-
dence that VEGF plays a central role in the development
and growth of ovarian cancer, information regarding the
clinical utility of serum VEGF levels is limited and incon-
clusive. VEGF has been detected in tissue and serum of
patients with ovarian cancer [27-33]. It was shown that
the serum levels of VEGF are significantly elevated in
patients with epithelial ovarian cancer compared to levels
in patients with benign disease [33]. In the largest pub-
lished analysis of 314 patients with ovarian cancer, high
preoperative VEGF serum concentrations were associ-
ated with decreased overall survival by multivariate anal-
ysis [31]. Several other studies produced conflicting
results regarding the prognostic impact of serum VEGF
[27,28,30,32,34-40]. However, the variation of serum
VEGF values in the course of treatment has not been
studied since many of these studies used 'pre-treatment'
samples and did not separate between pre- and postoper-
ative serum samples or clearly define time points of
serum collection.
When comparing different study results there is a high
variability of VEGF serum levels, which might be caused
by differences in assay techniques (many assays have no
specificity for different VEGF-isoforms), storage of speci-
mens and the small number of samples analyzed in most
Table 3: Correlations between serum concentration of CA-125, TIMP-1 and VEGF and survival
PFS OS
p-value +/- p-value +/-
CA-125 before surgery 0.593 . 0.629 .
CA-125 before CTX 0.725 . 0.033* -
CA-125 during CTX 0.627 . 0.308 .
CA-125 after CTX <0.001 + 0.002* +
TIMP-1 before surgery 0.534 . 0.195 .
TIMP-1 before CTX 0.499 . 0.980 .
TIMP-1 during CTX 0.781 . 0.380 .
TIMP-1 after CTX 0.152 . 0.007 +
VEGF before surgery 0.352 . 0.302 .
VEGF before CTX 0.043 + 0.230 .
VEGF during CTX 0.946 . 0.496 .
VEGF after CTX 0.006 + 0.023 +
Correlations between serum concentration of CA-125, TIMP-1 and VEGF (below/above median) and survival. For progression-free survival 
(PFS) and overall survival (OS): p-values from the log-rank-test. +/- indicates the direction of a significant correlation. A positive correlation 
indicates a higher likelihood of an event (e.g. elevated CA-125 is associated with high likelihood of disease progression).Mahner et al. BMC Cancer 2010, 10:139
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Table 4: Correlations between serum concentration of CA-125, TIMP-1 and VEGF and clinicopathological factors
Age Residual 
Tumor
Ascites pN Grading
p-value +/- p-value +/- p-value +/- p-value +/- p-value +/-
CA-125 
before 
surgery
0.046 + 0.631 . 0.004 + 0.254* 0.121*
CA-125 
before CTX
0.169 . 0.619 . 0.619 . 1.000* 0.118*
CA-125 
during CTX
0.238 . 0.533 . 0.774 . 0.440* 1.000*
CA-125 
after CTX
0.300 . 0.948 . 0.275 . 0.339* 0.238*
TIMP-1 
before 
surgery
0.273 . 0.812 . 0.096 . 0.423* 0.682*
TIMP-1 
before CTX
0.387 . 0.169 . 0.430 . 0.414* 1.000*
TIMP-1 
during CTX
0.229 . 0.934 . 0.201 . 0.257* 0.429*
TIMP-1 after 
CTX
0.086 . 0.157* . 0.032* + 0.218* 0.688*
VEGF 
before 
surgery
0.273 . 0.597 . 0.550 . 1.000* 0.08*
VEGF 
before CTX
0.221 . 0.280 . 0.946 . 0.226* 1.000*
VEGF 
during CTX
0.395 . 0.724 . 0.486 . 1.000 0.688*
VEGF after 
CTX
0.303 . 0.829 . 0.829 . 0.110* 0.688*
Correlations between serum concentration of CA-125, TIMP-1 and VEGF (below/above median) and clinicopathological factors. A positive 
correlation indicates a higher likelihood of an event. P-values from the Pearson-Chi2-Test and from Fisher's exact test (*) are reported for binary 
correlations with age: <61 years versus 61 years or older; ascites: <500 ml versus >500 ml; residual tumor after surgery: microscopic versus 
macroscopic; lymph node status: no metastasis versus lymph-node metastasis; grading: G2 versus G3. +/- indicates the direction of a significant 
correlation.Mahner et al. BMC Cancer 2010, 10:139
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studies. Furthermore, there is no clearly defined 'cut-off'
to classify serum VEGF concentrations as elevated or
normal. This complicates cross trial comparison and was
our rationale to use median values as 'cut-off' for the
analyses. With this approach, pre- or postoperative
VEGF-165 had no prognostic significance. In the current
study, we observed a significant increase between pre-
and postoperative serum VEGF-165 levels (p = 0.01, Fig-
ure 1, Table 2). Moreover, we found a significant consecu-
tive decrease of serum VEGF-165 during chemotherapy
(p < 0.001). These results suggest that serum VEGF-165
may be helpful in therapy monitoring and surveillance of
ovarian cancer patients and can provide additional infor-
mation to CA-125 measurements. Given the high inter-
study-variability of VEGF serum levels, a longitudinal
measurement of individual patient levels might be a bet-
ter approach than the assessment of absolute values at
single time-points.
The prognostic potential of VEGF-165 levels after che-
motherapy has also been described in a study evaluating
the role of serum VEGF-165 in patients with complete
response after first-line therapy [41]. These patients
underwent second look surgery and women with persis-
tent disease had higher VEGF serum levels. Taken
together, these findings might add to the rationale of anti-
VEGF therapy after completion of surgical and cytostatic
first-line therapy of ovarian cancer, a concept currently
under investigation in large phase III trials [42].
In contrast to previous findings by Li et al. [34] and
Oehler et al. [36] we observed an initial postoperative
increase of VEGF-165 and consecutive decrease during
and after chemotherapy. The large wound area and heal-
ing process after radical debulking surgery often includ-
ing extensive peritonectomy could explain the increase of
angiogenic factors, as previously described for other
malignancies [43]. Another reason for this difference
might be the delayed collection of blood samples in the
other series. Oehler et al. collected samples 4 weeks after
surgery, a time at which most healing processes are
already completed whereas in our study postoperative
serum was collected within the first 7 days after surgery.
Matrix Metalloproteinases (MMPs) play a key role in
invasion and metastasis of cancer cells. They are able to
degrade extracellular matrix and aid angiogenesis [44].
MMPs can be regulated by their inhibitors, the tissue
inhibitor of metalloproteinases (TIMPs) [45]. In addition
to this regulatory role, TIMPs possess pro-tumorigenic
and metastatic activity [46]. Increased expression of
TIMP-1 has been associated with unfavourable outcome
in several tumor types [47,48]. For ovarian cancer, con-
flicting results have been reported showing both up- and
downregulation of TIMP-1 [49-51]. Rauvala et al. studied
the level of TIMP-1 in preoperative serum of patients
Table 5: Correlations between serum concentrations of VEGF-165 and TIMP-1 and response to first-line treatment 
according to decrease of CA-125.
Response (% decrease of CA-125)
p-value correlation coefficient r
TIMP-1 before surgery 0.375 0.174
TIMP-1 before CTX 0.150 0.265
TIMP-1 during CTX 0.480 0.127
TIMP-1 after CTX 0.554 0.107
VEGF before surgery 0.725 -0.07
VEGF before CTX 0.729 0.065
VEGF during CTX 0.414 -0.147
VEGF after CTX 0.671 -0.077
P-values according to the Pearson correlation coefficients using continous serum values and relative decrease of CA-125.Mahner et al. BMC Cancer 2010, 10:139
http://www.biomedcentral.com/1471-2407/10/139
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Figure 3 Kaplan-Meier plots of progression-free survival (left) and overall survival (right) for serum concentrations of CA-125 after chemo-
therapy, TIMP-1 after chemotherapy, VEGF-165 before chemotherapy and VEGF-165 after chemotherapy. Dotted line: below median; solid-
line: above median.
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with ovarian cancer [52]. They found an elevated preop-
erative serum TIMP-1 to be associated with unfavourable
clinical outcome, as previously suggested in a smaller
study by Manenti et al. [40]. A negative prognostic impact
of serum TIMP-1 has also been observed in breast cancer,
colorectal cancer and other malignancies [53,54]. In the
current study, we observed no correlation between pre-
or postoperative serum concentrations of TIMP-1 and
outcome (Table 3). However, low serum concentration at
the end of chemotherapy was associated with improved
overall survival (p = 0.007). Of note, TIMP-1 serum levels
were closely correlated with VEGF-165 at all time-points
(Figure 1 and 2). This could reflect common regulatory
mechanisms and confirm the biological connection of
both factors in ovarian cancer, leading to degradation of
basement membranes and extracellular matrix as well as
neovascularization.
In contrast to CA-125, a "normal value" could not be
defined for TIMP-1 and VEGF-165 and different cut-off
values have been used in previous studies [18,19,25,27-
41,47,53-56]. We therefore assume that a longitudinal
measurement of individual patient levels - using each
patient as their own control - might be a better approach
than the assessment of absolute values at single time-
points.
Limitations of our study are the relatively small number
of patients, its mono-centric design and the fact that sam-
ples were not strictly collected in consecutive patients,
leading to a possible selection bias. However, the uniform
treatment and high rate of patients with optimal surgical
cytoreduction followed by platinum based combination
chemotherapy might be a strength of this study. Biologi-
cal markers are more likely to be detectable in patients
without residual tumor burden, the most important unfa-
vourable prognostic factor.
Conclusion
This study is the first comprehensive longitudinal analysis
of serum VEGF-165 and TIMP-1 in patients with ovarian
cancer. It demonstrates that these markers change sub-
stantially during first-line therapy, are not correlated with
CA-125 and might have prognostic relevance, suggesting
a potential role in the surveillance of women with ovarian
cancer. To further understand this role, the evaluation of
TIMP-1 and VEGF in the context of prospective clinical
trials is highly desirable.
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